Defining Endpoints in Becker Muscular Dystrophy
- Conditions
- Muscular Dystrophy in ChildrenMuscular DystrophiesBecker Muscular DystrophyMuscular Dystrophy, Becker
- Registration Number
- NCT05257473
- Lead Sponsor
- Virginia Commonwealth University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 80
Inclusion Criteria:<br><br>For ages 6-12<br><br> 1. Clinically affected (defined as weakness on bedside evaluation in a pattern<br> consistent with BMD)<br><br> 2. Genetic confirmation of an in-frame dystrophin mutation<br><br> 3. Ambulatory<br><br> 4. Willing and able to give informed consent and follow all procedures and requirements<br><br>For ages 13 and older<br><br> 1. Clinically affected (defined as weakness on bedside evaluation in a pattern<br> consistent with BMD)<br><br> 2. Genetic confirmation of a dystrophin mutation<br><br> 3. Willing and able to give informed consent and follow all procedures and requirements<br><br>For participants in the MRI substudy:<br><br> 1. Ambulatory, defined as able to walk 10 meters without assistive devices (orthotics<br> allowed)<br><br>Exclusion Criteria:<br><br>For ages 6-12<br><br> 1. Out of frame dystrophin mutation<br><br> 2. Use of chronic corticosteroids at baseline, defined as greater than 6 months of<br> chronic use, will be limited to 20% of the overall population<br><br> 3. Non-ambulatory, defined as the inability to walk 10 meters without assistive device<br> (excluding orthotics)<br><br> 4. >16 hours of ventilatory support<br><br> 5. Any other illness that would interfere with the ability to undergo safe testing or<br> would interfere with interpretation of the results in the opinion of the site<br> investigator.<br><br> 6. Under the age of 6 at time of enrollment<br><br> 7. For MR Cohort: Have contraindications to MRI or MRS (e.g., non-MR compatible<br> implanted medical devices or severe claustrophobia)<br><br>For ages 13 and older<br><br> 1. Loss of ambulation prior to age 16<br><br> 2. Use of chronic corticosteroids, defined as greater than 6 months of chronic use,<br> will be limited to 20% of the overall population<br><br> 3. Less than 30% of the overall population will be non-ambulatory, defined as the<br> inability to walk 10 meters without assistive device (excluding orthotics)<br><br> 4. >16 hours of ventilatory support<br><br> 5. Subjects aged 13-16 only: time to rise >10 seconds<br><br> 6. For MR Cohort: Have contraindications to MRI or MRS (e.g., non-MR compatible<br> implanted medical devices or severe claustrophobia)
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the natural history of measures of muscle function in BMD;4-Stair Climb;100-Meter Timed Test;PERFORMANCE OF UPPER LIMB 2.0 (PUL);HAND HELD DYNAMOMETRY (HHD) AND GRIP;TIMED UP-AND-GO (TUG);Measures of Pulmonary Function (Seated and supine FVC);Measures of Pulmonary Function (MEP and MIP);Measures of Pulmonary Function (other);Measure of ejection fraction (ECHO);Measure of systolic and diastolic function (ECHO)
- Secondary Outcome Measures
Name Time Method